EDINBURGH, Scotland--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in ...
DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...
DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three years ...
Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are two leading medical device companies that compete against one ...
DexCom is expected to remain an outperformer in the healthcare sector in 2024, driven by M&A activity and the growth of GLP-1 weight loss drugs. The company's continuous glucose monitoring ("CGM") ...
Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...
DexCom posted another quarter of robust top-line growth that leaves the firm on track to meet our full-year expectations, and we’re standing behind our $315 fair value estimate. Importantly, DexCom’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results